Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Non-Current Liabilities (2023 - 2025)

Verrica Pharmaceuticals has reported Total Non-Current Liabilities over the past 3 years, most recently at $22.4 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $22.4 million for Q4 2025, down 63.51% from a year ago — trailing twelve months through Dec 2025 was $22.4 million (down 63.51% YoY), and the annual figure for FY2025 was $22.4 million, down 63.51%.
  • Total Non-Current Liabilities for Q4 2025 was $22.4 million at Verrica Pharmaceuticals, down from $56.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for VRCA hit a ceiling of $61.8 million in Q4 2023 and a floor of $6.8 million in Q2 2023.
  • Median Total Non-Current Liabilities over the past 3 years was $55.5 million (2023), compared with a mean of $47.1 million.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 0.79% in 2024 and later plummeted 63.51% in 2025.
  • Verrica Pharmaceuticals' Total Non-Current Liabilities stood at $61.8 million in 2023, then decreased by 0.79% to $61.3 million in 2024, then plummeted by 63.51% to $22.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $22.4 million (Q4 2025), $56.2 million (Q3 2025), and $54.8 million (Q2 2025) per Business Quant data.